Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Acquisition
Details : New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
February 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Chiesi Group
Deal Size : Undisclosed
Deal Type : Acquisition